Publications

Yan Lin, PhD

Vujanovic L, Chuckran C, Lin Y, Ding F, Sander CA, Santos PM, Lohr J, Mashadi-Hossein A, Warren S, White A, Huang A, Kirkwood JM, Butterfield LH. CD56dim CD16- Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-α. Front Immunol. 2019;1014. doi: 10.3389/fimmu.2019.00014. PubMed PMID: 30761123; PMCID: PMC6361792.
Kansy BA, Shayan G, Jie HB, Gibson SP, Lei YL, Brandau S, Lang S, Schmitt NC, Ding F, Lin Y, Ferris RL. T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response. Oncoimmunology. 2018;7(11):e1494112. doi: 10.1080/2162402X.2018.1494112. PubMed PMID: 30377562; PMCID: PMC6205044.
Tarhini A, Lin Y, Lin H, Rahman Z, Vallabhaneni P, Mendiratta P, Pingpank JF, Holtzman MP, Yusko EC, Rytlewski JA, Rao UNM, Ferris RL, Kirkwood JM. Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire. J Immunother Cancer. 2018 Oct 23;6(1):112. doi: 10.1186/s40425-018-0428-5. PubMed PMID: 30352626; PMCID: PMC6199801.
Yoneyama T, Gorry M, Sobo-Vujanovic A, Lin Y, Vujanovic L, Gaither-Davis A, Moss ML, Miller MA, Griffith LG, Lauffenburger DA, Stabile LP, Herman J, Vujanovic NL. ADAM10 Sheddase Activity is a Potential Lung-Cancer Biomarker. J Cancer. 2018;9(14):2559-2570. doi: 10.7150/jca.24601. PubMed PMID: 30026855; PMCID: PMC6036891.
Retseck J, Nasr A, Lin Y, Lin H, Mendiratta P, Butterfield LH, Tarhini AA. Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma. J Transl Med. 2018 Jul 4;16(1):184. doi: 10.1186/s12967-018-1563-y. PubMed PMID: 29973204; PMCID: PMC6033230.
Özbek U, Lin HM, Lin Y, Weeks DE, Chen W, Shaffer JR, Purcell SM, Feingold E. Statistics for X-chromosome associations. Genet Epidemiol. 2018 Sep;42(6):539-550. doi: 10.1002/gepi.22132. PubMed PMID: 29900581; PMCID: PMC6394852.
Tahata S, Singh SV, Lin Y, Hahm ER, Beumer JH, Christner SM, Rao UN, Sander C, Tarhini AA, Tawbi H, Ferris LK, Wilson M, Rose A, Dietz CM, Hughes E, Fahey JW, Leachman SA, Cassidy PB, Butterfield LH, Zarour HM, Kirkwood JM. Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi. Cancer Prev Res (Phila). 2018 Jul;11(7):429-438. doi: 10.1158/1940-6207.CAPR-17-0268. PubMed PMID: 29691233; PMCID: PMC6030491.
Yoneyama T, Gorry M, Miller MA, Gaither-Davis A, Lin Y, Moss ML, Griffith LG, Lauffenburger DA, Stabile LP, Herman JG, Vujanovic NL. Modification of proteolytic activity matrix analysis (PrAMA) to measure ADAM10 and ADAM17 sheddase activities in cell and tissue lysates. J Cancer. 2017;8(19):3916-3932. doi: 10.7150/jca.20779. PubMed PMID: 29187866; PMCID: PMC5705993.
Tarhini AA, Floros T, Lin HM, Lin Y, Rahman Z, Ashraf M, Vallabhaneni P, Sander C, Rao UNM, Panelli M, LaFramboise WA, Kirkwood JM. A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma. Melanoma Res. 2017 Oct;27(5):429-438. doi: 10.1097/CMR.0000000000000383. PubMed PMID: 28825947; PMCID: PMC5657445.
Stoller R, Schmitz JC, Ding F, Puhalla S, Belani CP, Appleman L, Lin Y, Jiang Y, Almokadem S, Petro D, Holleran J, Kiesel BF, Ken Czambel R, Carneiro BA, Kontopodis E, Hershberger PA, Rachid M, Chen A, Chu E, Beumer JH. Phase I study of veliparib in combination with gemcitabine. Cancer Chemother Pharmacol. 2017 Sep;80(3):631-643. doi: 10.1007/s00280-017-3409-3. PubMed PMID: 28770300; PMCID: PMC5734661.
Tarhini AA, Moschos SJ, Lin Y, Lin HM, Sander C, Yin Y, Venhaus R, Gajewski TF, Kirkwood JM. Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma. Melanoma Res. 2017 Aug;27(4):342-350. doi: 10.1097/CMR.0000000000000353. PubMed PMID: 28489678.
Tarhini AA, Lin Y, Lin HM, Vallabhaneni P, Sander C, LaFramboise W, Hamieh L. Expression profiles of immune-related genes are associated with neoadjuvant ipilimumab clinical benefit. Oncoimmunology. 2017;6(2):e1231291. doi: 10.1080/2162402X.2016.1231291. PubMed PMID: 28344862; PMCID: PMC5353928.
Ferris LK, Saul MI, Lin Y, Ding F, Weinstock MA, Geller AC, Yuan JM, Neuren E, Maddukuri S, Solano FX, Kirkwood JM. A Large Skin Cancer Screening Quality Initiative: Description and First-Year Outcomes. JAMA Oncol. 2017 Aug 1;3(8):1112-1115. doi: 10.1001/jamaoncol.2016.6779. PubMed PMID: 28241191; PMCID: PMC5552417.
Najjar YG, Ding F, Lin Y, VanderWeele R, Butterfield LH, Tarhini AA. Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab. J Transl Med. 2017 Feb 21;15(1):39. doi: 10.1186/s12967-017-1140-9. PubMed PMID: 28222797; PMCID: PMC5319167.
Gyanchandani R, Lin Y, Lin HM, Cooper K, Normolle DP, Brufsky A, Fastuca M, Crosson W, Oesterreich S, Davidson NE, Bhargava R, Dabbs DJ, Lee AV. Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer. Clin Cancer Res. 2016 Nov 1;22(21):5362-5369. doi: 10.1158/1078-0432.CCR-15-2889. PubMed PMID: 27185370; PMCID: PMC5093028.
Retseck J, VanderWeele R, Lin HM, Lin Y, Butterfield LH, Tarhini AA. Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab. J Immunother Cancer. 2016;438. doi: 10.1186/s40425-016-0141-1. PubMed PMID: 27330811; PMCID: PMC4915044.
Roth CG, Gillespie-Twardy A, Marks S, Agha M, Raptis A, Hou JZ, Farah R, Lin Y, Qian Y, Pantanowitz L, Boyiadzis M. Flow Cytometric Evaluation of Double/Triple Hit Lymphoma. Oncol Res. 2016;23(3):137-46. doi: 10.3727/096504015X14500972666761. PubMed PMID: 26931436.
Sobo-Vujanovic A, Vujanovic L, DeLeo AB, Concha-Benavente F, Ferris RL, Lin Y, Vujanovic NL. Inhibition of Soluble Tumor Necrosis Factor Prevents Chemically Induced Carcinogenesis in Mice. Cancer Immunol Res. 2016 May;4(5):441-51. doi: 10.1158/2326-6066.CIR-15-0104. PubMed PMID: 26896171; PMCID: PMC4873325.
Siegfried JM, Lin Y, Diergaarde B, Lin HM, Dacic S, Pennathur A, Weissfeld JL, Romkes M, Nukui T, Stabile LP. Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome. Neoplasia. 2015 Nov;17(11):817-25. doi: 10.1016/j.neo.2015.11.002. PubMed PMID: 26678909; PMCID: PMC4681883.
Tarhini AA, Zahoor H, Lin Y, Malhotra U, Sander C, Butterfield LH, Kirkwood JM. Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer. 2015;339. doi: 10.1186/s40425-015-0081-1. PubMed PMID: 26380086; PMCID: PMC4570556.
Weissfeld JL, Lin Y, Lin HM, Kurland BF, Wilson DO, Fuhrman CR, Pennathur A, Romkes M, Nukui T, Yuan JM, Siegfried JM, Diergaarde B. Lung Cancer Risk Prediction Using Common SNPs Located in GWAS-Identified Susceptibility Regions. J Thorac Oncol. 2015 Nov;10(11):1538-45. doi: 10.1097/JTO.0000000000000666. PubMed PMID: 26352532; PMCID: PMC4636453.
Tarhini AA, Lin Y, Zahoor H, Shuai Y, Butterfield LH, Ringquist S, Gogas H, Sander C, Lee S, Agarwala SS, Kirwood JM. Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients. PLoS One. 2015;10(7):e0132745. doi: 10.1371/journal.pone.0132745. PubMed PMID: 26192408; PMCID: PMC4508028.
Ross K, Gillespie-Twardy AL, Agha M, Raptis A, Hou JZ, Farah R, Redner RL, Im A, Duggal S, Ding F, Lin Y, Boyiadzis M. Intensive chemotherapy in patients aged 70 years or older newly diagnosed with acute myeloid leukemia. Oncol Res. 2015;22(2):85-92. doi: 10.3727/096504014X14146137738547. PubMed PMID: 25706395.
Davar D, Lin Y, Kirkwood JM. Unfolding the mutational landscape of human melanoma. J Invest Dermatol. 2015 Mar;135(3):659-662. doi: 10.1038/jid.2014.467. PubMed PMID: 25666674; PMCID: PMC4466551.

<< Investigators Search

Top